Canadian immunologist and cell biologist at Rockefeller University

Canadian immunologist and cell biologist at Rockefeller University “ Discovery of the dendritic cell and its role in adaptive immunity” The Nobel Prize in Physiology or Medicine 2011 (Awarded Posthumously) Ralph M. Steinman, Ph. D. (January 14, 1943 – September 30, 2011)

DISRUPTIVE TECHNOLOGY IN THE PERSONALIZED MEDICINE AGE OF PERSONALIZED MEDICINE FRANCISCO S. CHUNG JR. Ph. D Co Director Cellular Therapeutics Center Makati Medical Center

Disclosure: Clinical data to be presented are in accordance to Helsinki Declaration The World Medical Association (WMA) has developed the Declaration of Helsinki as a statement of ethical principles for medical research involving human subjects, including research on identifiable human material and data. International Ethical Guidelines for Biomedical Research Involving Human Subjects by World Health Organization (WHO) and Council for International Organizations of Medical Sciences (CIOMS)

DEFINING PERSONALIZED MEDICINE “It’s far more important to know what person the disease has than what disease the person has. ” – Hippocrates

Early Examples of Personalized Medicine • 1907: Reuben Ottenberg reports the first known blood compatibility test for transfusion using blood typing techniques and cross-matching between donors and patients to prevent hemolytic transfusion reactions. • 1956: The genetic basis for the selective toxicity of fava beans (favism) and the antimalarial drug primaquine is discovered to be a deficiency in the metabolic enzyme, glucose-6 -phosphate dehydrogenase (G 6 PD). • 1977: Cytochrome P 450 2 D 6, a polymorphic metabolizing enzyme, is identified as the culprit for causing some patients to experience an “overdose” or exaggeration of the duration and intensity of the effects of debrisoquine, a drug used for treating hypertension.

Megatrends Impacting the Entire Spectrum of Care A modern health care system is on the horizon, demanding a paradigm shift One Size Fits All Fragmented, One-way Provider Centric Centralized, Hospital Based Fragmented Specialized APPROACH INFORMATION FLOW FOCUS Peronalized Medicine Integrated, Two Way Patient Centric LOCATION Decentralized Community-based TREATMENT Collaborative Shared Information Procedure-based REIMBURSEMENT Treating Sickness OBJECTIVE Outcomes-based Preventing Sickness (Wellness) Source: Frost & Sullivan

Four Essential Components for a Successful Personalized Medicine : G. I. F. T Model

MOLECULAR DIAGNOSTICS ACROSS MEDICAL DISCIPLINES CIRCULATING TUMOR CELLS ASSAY

ECONOMICS OF MOLECULAR DIAGNOSTICS

INTEGRATING MOLECULAR DIAGNOSTICS WITH THERAPEUTICS

CHANGING TREATMENT PROTOCOLS IN CLINICAL PRACTICE

MARKET DEVELOPMENTS FOR PERSONALIZED MEDICINE IN MOLECULAR DIAGNOSTIC TESTS • Molecular diagnostics market has grown at double-digit pace, achieving an overall 14% CAGR (Compound Annual Growth Rate) to meet increasing demand for personalized medicine as of 2015. • Key areas of growth a. b. c. d. Infectious diseases Oncology Genetic testing Blood banking

CONCLUSIONS • Personalized Medicine promises more precise, efficient patient care. • The infrastructure of a successful personalized medicine center should have FOUR ESSENTIAL COMPONENTS: 1. Genomic/molecular data acquisition and storage, 2. Integration of genomic diagnostic testing and targeted imaging, 3. Research focused on functional genomic targets, and 4. Development and informed use of targeted therapies of actionable genes. • Moving forward, clear and centralized consensus on actionable genes is needed.

REFERENCES AND CREDITS • • • http: //www. fda. gov/downloads/Science. Research/Special. Topics/Personalized. Medicine/UCM 372421. pdf http: //www. asiabiotech. com/17/17120028 x. html http: //medtechevents. blogspot. com/2016_01_01_archive. html http: //alliancerm. org/page/clinical-trials-products http: //www. cellr 4. org/article/856 Constance, J. A. (2010). The future of molecular diagnostics- Innovative technologies driving market opportunities in personalized medicine. Business Insights Ltd. • SLIDE CREDITS – Kimberly Semon, Laboratory Manager, Cellular Therapeutics Center and Von Luigi Valero